Charles River Laboratories (CRL)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 76.43% | 79.81% | 78.04% | 36.52% | 37.11% |
| Operating profit margin | 15.12% | 15.88% | 17.06% | 14.72% | 13.60% |
| Pretax margin | 14.10% | 15.05% | 13.68% | 15.18% | 11.70% |
| Net profit margin | 11.62% | 11.86% | 11.31% | 12.39% | 9.76% |
Charles River Laboratories has shown consistent profitability over the past five years, as evidenced by positive trends in its profitability ratios. The gross profit margin has exhibited fluctuations but generally remained high, with the latest figure at 76.43% indicating healthy revenue generation after deducting the cost of goods sold.
The operating profit margin has also been fairly stable, hovering around the 15-17% range over the period, reflecting the company's ability to control its operating expenses effectively. This indicates that Charles River Laboratories has been efficient in managing its day-to-day operations to generate profits.
The pretax margin has shown some variability but has generally been above 10% throughout the years, suggesting that the company has been successful in generating earnings before accounting for income taxes. This margin represents the profitability of the company before considering the impact of taxes and provides insights into its operational efficiency.
Lastly, the net profit margin, which measures the company's bottom line profitability after all expenses, has shown an improving trend over the years, reaching 11.62% in 2023. This indicates that Charles River Laboratories has been effective in managing its overall expenses and is generating a healthy level of net income relative to its total revenue.
Overall, the profitability ratios of Charles River Laboratories reflect a financially sound business with a strong focus on generating profits and maintaining efficiency in its operations.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.53% | 8.56% | 8.40% | 7.88% | 7.48% |
| Return on assets (ROA) | 5.79% | 6.40% | 5.57% | 6.63% | 5.37% |
| Return on total capital | 19.80% | 22.71% | 21.57% | 25.18% | 22.20% |
| Return on equity (ROE) | 13.20% | 16.34% | 15.42% | 17.23% | 15.42% |
Charles River Laboratories has shown consistent profitability over the past five years, with varying levels of return on assets (ROA) and return on equity (ROE). The operating return on assets (Operating ROA) has ranged from 7.48% to 8.56%, indicating the company's ability to generate operating profits relative to its total assets. The overall ROA has also remained relatively stable between 5.37% to 6.63%, reflecting the company's overall profitability in generating net income from its assets.
Return on total capital has fluctuated between 19.80% to 25.18%, indicating the company's efficiency in generating returns from its total capital investments. The return on equity (ROE) has ranged from 15.42% to 17.23%, showcasing the company's ability to generate returns for its shareholders relative to their equity investment.
Overall, Charles River Laboratories has maintained a solid level of profitability as evidenced by its profitability ratios, demonstrating effective management of assets and capital to generate returns for both the company and its shareholders.